J Clin Oncol 2010 28: 1878–1887.įunding Support for this study was provided by the Cancer Outcomes and Survivorship Pilot Grant through the University of Minnesota Masonic Cancer Center. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. Measuring costs: administrative claims data, clinical trials, and beyond. Med Care 2009 47: S51–S55.Įtzioni R, Riley GF, Ramsey SD, Brown M. Administrative and claims records as sources of health care cost data. Assessing quality using administrative data. Allogeneic transplant physician and center capacity in the United States. Majhail NS, Murphy EA, Omondi NA, Majhail NS, Murphy EA, Omondi NA et al. Individual physician practice variation in hematopoietic cell transplantation. Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M et al. Variation in supportive care practices in hematopoietic cell transplantation. Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R et al. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999 17: 2811–2818. Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2007 40: 209–217.īennett C, Waters T, Stinson T, Almagor O, Pavletic Z, Tarantolo S et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP et al. Predicting costs of stem-cell transplantation. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. Costs of pediatric allogeneic hematopoietic-cell transplantation. ![]() ![]() Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE et al. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Agency for Healthcare Research and Quality: Rockville, MD. Procedures with the most rapidly increasing hospital costs, 2004–2007, HCUP Statistical Brief #82. Our study lays the foundation for using claims data for future research on economic aspects of HCT. Using a claims database representing a national HCT population, we highlight the high costs associated with autologous and allogeneic HCT. Costs were greater among pediatric ( ⩽20 years) compared with adult (>20 years) recipients and this difference was more pronounced with allogeneic HCT. The majority of costs (>75%) occurred during the initial transplant hospitalization for both autologous and allogeneic HCT recipients. ![]() Using ICD-9 procedure and diagnosis codes, we identified 3365 patients who had received their first transplant in the United States between 20 (autologous, 1678, allogeneic, 1320, graft source not specified, 367). ![]() We used a single longitudinal administrative claims database representing a national, commercially insured population to evaluate the feasibility of identifying HCT recipients and to establish a cohort of autologous and allogeneic HCT recipients to study inpatient and outpatient direct medical costs from transplant hospitalization through first 100 days post-transplantation. There is a lack of multi-center cost-identification studies for hematopoietic cell transplantation (HCT).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |